FIELD: medicine. SUBSTANCE: method involves taking blood sample, stabilizing the sample, separating plasma reach in blood platelets by means of centrifuging, adding anti-aggregation agent, mixing and incubating plasma with and without the preparation at 36.5-37.5 C. Test system having anti-aggregation preparations of various mechanisms anti- aggregation activity with respect to blood platelets is applied. Preparation concentration in the test system is selected starting from the taken single dose. Blood platelets aggregation level index is to be determined before and after introducing the anti-aggregation preparation as adenosine diphosphate-induced blood platelets aggregation. Adenosine diphosphate-induced blood platelets aggregation of a preparation being by 50% and more different from the control sample, the preparation is considered to be efficient. EFFECT: enhanced effectiveness in individually selecting preparations.
Title | Year | Author | Number |
---|---|---|---|
METHOD OF REDUCING AGGREGATION ACTIVITY OF PLATELETS in vitro | 2009 |
|
RU2410104C1 |
METHOD FOR OPTIMIZATION OF ANTIAGGREGATIONAL THERAPY IN PATIENTS WITH CEREBROVASCULAR DISEASES | 2000 |
|
RU2188008C2 |
METHOD FOR PATIENT-SPECIFIC SELECTION OF ANTIPLATELET DRUGS FOR PATIENTS IN NEED THEREOF | 2012 |
|
RU2499261C1 |
MEANS FOR INTENSIFYING ANTIAGGREGATION EFFECT OF ASPIRIN | 1991 |
|
RU2007170C1 |
METHOD FOR DETECTING ANTIPLATELET DRUG RESISTANCE IN PATIENTS WITH PROGRESSING CEREBRAL ATHEROSCLEROSIS | 2012 |
|
RU2478965C1 |
AGENT SHOWING ANTIAGGREGATION ACTIVITY | 1991 |
|
RU2061481C1 |
PRODUCT WITH ANTIAGGREGATION AND ANTICOAGULANT EFFECTS, AND METHOD OF ITS PREPARATION | 2023 |
|
RU2808110C1 |
AGENT SHOWING ANTIAGGREGATION ACTIVITY | 1990 |
|
RU2033791C1 |
SUBSTITUTED ω-AZOLYLALKANE ANILIDES, METHOD FOR THEIR PREPARING AND USING AS ANTI-AGGREGATING AGENT | 2006 |
|
RU2322440C1 |
ANTIAGGREGANT | 2005 |
|
RU2353363C2 |
Authors
Dates
2002-08-27—Published
2000-06-27—Filed